| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
DEERFIELD, Ill.—Advanced Clinical, a clinical development organization providing contract research, functional service provider, strategic resourcing and quality and validation services, announced in late June that it has joined Align Clinical CRO, a new industry standards group dedicated to making it easier for sponsors and contract research organizations to work together during clinical trials.
 
“Align Clinical CRO’s mission is directly in line with our goal of delivering a better clinical experience to sponsors. As a member of this powerful industry collaboration, we will help develop and drive new technology standards that will improve operational delivery of clinical trials,” said Julie Ross, president of Advanced Clinical.
 
Align Clinical CRO aims to develop and support the adoption of open technology standards that make it easier for industry sponsors and CROs to collaborate and execute clinical trials. Founded by Veeva Systems and leading CROs, the group’s first standard for operational data exchange will define the data and structure that technology companies can implement in order to consistently and easily exchange clinical trial data between CROs and sponsors. With more efficient CRO-sponsor data exchange, these standards will reduce clinical trial start up time and operational costs while improving data integrity and service delivery.
 
The Operational Data Exchange Standard is expected to be published for public review and input later this year.

Related Topics

Published In

Volume 14 - Issue 7 | July 2018

July 2018

July 2018 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue